PACB - Pacific Biosciences of California logo

Pacific Biosciences of California

PACB

Pacific Biosciences of California designs and manufactures sequencing solutions, including long-read and short-read systems, consumables, and reagents. Its products serve academic, governmental, and commercial clients in genomics and biotechnology.

⚕️ Healthcare NASDAQ Listed 2010 $ USD
$1,000 invested 10 years ago →$207today

Score Overview

1 Year
Score
Net Growth75.95%
Net TrendGrew
Net Income Consistency—
Rev Growth-0.46%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.0
Net Growth27.50%
Net Trend40%
Net Income Consistency—
Rev Growth22.03%
Rev Trend40%
Revenue Consistency—
10 Years
Score
Net Growth-76.65%
Net Trend40%
Net Income Consistency
Rev Growth75.57%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth6.26%
Net Trend56%
Net Income Consistency
Rev Growth95x
Rev Trend56%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Pacific Biosciences of California has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • PACB

2016: 17.0% · 2021: 67.3% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 1.83—
1 Year2025-09-29
$ 1.2546.40%
5 Years2021-09-29
$ 24.86-92.64%
10 Years2016-09-29
$ 8.82-79.25%
All Time2010-10-27
$ 16.44-88.87%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 159M-$ 131M$ 61M
2025$ 160M-$ 546M$ 279M
2024$ 154M-$ 309M$ 389M
2023$ 200M-$ 306M$ 631M
2022$ 128M-$ 314M$ 772M
2021$ 130M-$ 181M$ 1.04B
2020$ 78M$ 29M$ 318M
2019$ 90M-$ 84M$ 49M
2018$ 78M-$ 102M$ 102M
2017$ 93M-$ 92M$ 62M
2016$ 90M-$ 74M$ 71M
2015$ 92M-$ 31M$ 82M
2014$ 60M-$ 66M$ 101M
2013$ 28M-$ 79M$ 112M
2012$ 25M-$ 94M$ 100M
2011$ 33M-$ 109M$ 177M
IPO2010$ 1M-$ 140M$ 283M
PACB - Pacific Biosciences of California logo

Pacific Biosciences of California fundamental performance

Between 2020 and 2025, revenue grew from $ 78M to $ 160M and net income went from $ 29M to -$ 546M. Revenue increased in 2 of those 5 years; net income in 2.

Across Pacific Biosciences of California's full reported history, from 2010 to 2025, revenue grew from $ 1M to $ 160M and net income went from -$ 140M to -$ 546M. Revenue increased in 56% of the years measured; net income in 56%.

Pacific Biosciences of California currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Continue PACB’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies